The finding of anti-aquaporin-4 (AQP4) antibodies in the majority of patients with NMO [4] and some patients with NMOSD has advanced our pathogenic understanding of the disease [5] and has directed the therapeutic approach towards a B cell-directed therapy [6]. Here, AQP4 is linked to neuromyelitis optica.